A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients

Part of paid clinical trials in East Hanover, New Jersey.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07566988
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The aim of this study was to compare the effectiveness and economic burden of ofatumumab (OMB) and ocrelizumab (OCR) treatment in multiple sclerosis (MS) patients in the United States using data from an administrative claims database.

Key Dates

Start date
Oct 25, 2024
Status verified
Apr 2026
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025

Study Design

Enrollment
2,604 participants (actual)

Arms

  • Arm: Pooled OMB Cohort
    Adult MS patients, including treatment-naïve and treatment-experienced patients, with a first claim for OMB from August 20, 2020.
  • Arm: Pooled OCR Cohort
    Adult MS patients, including treatment-naïve and treatment-experienced patients, with a first claim for OCR from August 20, 2020.
  • Arm: Treatment-naïve OMB Cohort
    Adult MS patients who initiated OMB treatment and who did not use a DMT for MS treatment in the 12-month period before starting OMB.
  • Arm: Treatment-naïve OCR Cohort
    Adult MS patients who initiated OCR treatment and who did not use a DMT for MS treatment in the 12-month period before starting OCR.

Primary Outcome Measure

Annualized Relapse Rate (ARR) in Treatment-Naïve Patients [ Time Frame: Up to approximately 3 years and 11 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
NovartisEast HanoverNew Jersey07936-

Find similar trials in East Hanover, NJ

By condition
Multiple sclerosis
By specialty
NeurologyBrain disordersAutoimmune disease
By research site
Novartis· East Hanover, NJ

Related Studies